Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 multi-center, randomized, double-blind, placebo-controlled trial of LB-102 for the treatment of bipolar depression

Next Previous
Trial Profile

A Phase 2 multi-center, randomized, double-blind, placebo-controlled trial of LB-102 for the treatment of bipolar depression

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amisulpride (Primary)
  • Indications Bipolar depression; Bipolar I disorders
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ILLUMINATE-1

Most Recent Events

  • 26 Jan 2026 Status changed from planning to recruiting.
  • 26 Jan 2026 According to LB Pharmaceuticals media release, the company announced initiation of Phase 2 bipolar depression trial initiation follows positive Phase 2 results in acute schizophrenia, topline data expected in 1Q 2028. The trial will enroll at approximately 30 sites in the U.S.
  • 18 Nov 2025 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top